{"id":391649,"date":"2014-05-20T00:00:00","date_gmt":"2014-05-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasmd0314-biopharma-type-2-diabetes-inadequately-controlled-with-diet-and-exercise-first-line-drug-treatment\/"},"modified":"2026-04-27T11:31:25","modified_gmt":"2026-04-27T11:31:25","slug":"dbasmd0314-biopharma-type-2-diabetes-inadequately-controlled-with-diet-and-exercise-first-line-drug-treatment","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasmd0314-biopharma-type-2-diabetes-inadequately-controlled-with-diet-and-exercise-first-line-drug-treatment\/","title":{"rendered":"Type 2 Diabetes Inadequately Controlled with Diet and Exercise (First-Line Drug Treatment) | Decision Base | US\/EU | 2014"},"content":{"rendered":"<p><em>When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers?<\/em><\/p>\n<p>Affecting more than 30 million people in the United States alone, type 2 diabetes is a critical public health concern. Although diet and exercise are key initial and ongoing management strategies, drug treatment is inevitable for almost all patients. Metformin dominates the first-line drug treatment space, but some patients are unable to take metformin. Moreover, there is a trend way from the traditional stepwise approach to managing type 2 diabetes and toward individualizing therapy. With a broad and increasing range of treatments available, and a growing prevalence of disease, there is significant market opportunity for alternative first-line treatments.<\/p>\n","protected":false},"template":"","class_list":["post-391649","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391649\/revisions"}],"predecessor-version":[{"id":394772,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391649\/revisions\/394772"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}